Page 110 - 2021_07-Haematologica-web

L. Janssen et al.
28 ± 10 h/week, respectively; P=0.001).
Figure 3 shows the daily activity patterns of fatigued and
non-fatigued patients categorized into sleeping, sitting, light intensity physical activity, and moderate to vigorous phys- ical activity. Severely fatigued CML patients slept signifi- cantly longer than patients without fatigue (8.8 h/day [IQR 8.3-9.7] vs. 8.4 h/day [IQR 7.9-9.1]; P=0.006). Sitting time was not significantly different between the groups (P=0.43). Severely fatigued CML patients were significantly less
active when compared to non-fatigued patients as shown by both lower physical activity of light intensity (3.9 h/day [IQR 3.1-5.0] vs. 4.8 h/day [IQR 3.6-5.6]; P=0.017) and mod- erate to vigorous physical activity (0.9 h/day [IQR 0.6-1.2] vs. 1.1 h/day [IQR 0.8-1.3]; P=0.009). In line, step counts were significantly lower in CML patients with severe fatigue (7,464 ± 3,486 steps/day) than in patients without fatigue (9,393 ± 4,200 steps/day; P=0.004). After adjustment for gender and age, sleeping time remained longer and
Table 2. Characteristics of chronic myeloid leukemia patients with and without severe fatigue in part 2 of the study.
CML + fatigue CML – fatigue P-value
(N=67) (N=71)
Age,years 55±13 55±16 0.88
Gender, % female
BMI, kg/m2
Time since diagnosis, months
TKI type, % Imatinib
Dasatinib Nilotinib Bosutinib Ponatinib
TKI dose, (mg/day) Imatinib
Dasatinib Nilotinib Bosutinib Ponatinib
Treatment duration of current TKI, months
BCR-ABLIS transcript level, % MMR
Hemoglobin, mmol/L Male
Female
WBC count (x 109/L) Platelet count (x 109/L)
61 26.8 ± 4.7 67 (30-162)
37 27 16 15 5
400 (350-400) 100 (50-100) 600 (300-600) 350 (275-500) 30 (15-30)
35 (12-61) 87.3
8.5 ± 0.7 7.7 ± 0.9
6.3 ± 1.6
220 ± 61
44
26.0 ± 4.9 0.37
89 (39-153) 0.46 0.12
23 28 32 10 7
400 (400-400) 0.17 95 (70-100) 0.99 600 (600-600) 0.16 400 (400-400) 0.88 30 (15-37.50) 0.79
36 (16-79) 0.55 94.0 0.18
8.7 ± 0.9 0.24 8.0 ± 0.8 0.11
6.1 ± 1.7 0.49
221 ± 68 0.93
0.039
CML: chronic myeloid leukemia; BMI: body mass index; TKI: tyrosine kinase inhibitor; IS: international scale; MMR: major molecular response; WBC: white blood cell.
Figure 3. Activity patterns in severely fatigued and non-fatigued chronic myeloid leukemia patients. Daily time spent sleeping, sitting, performing light intensity phys- ical activity and moderate to vigorous intensity physical activity is shown for both severely fatigued and non-fatigued chronic myeloid leukemia patients. Box and whisker plots represent the median, interquartile range, and 2.5-97.5 percentiles (lower and upper whiskers, respectively). *P<0.05, **P<0.01, ns: not significant.
1880
haematologica | 2021; 106(7)